|
|
|
Good morning, 360! |
If you've been in the Market Master's Room lately, then you know Jeff Williams! We're passing on his complimentary training in Options Basics here… and just a quick note that $400 off his flagship options service is expiring at Noon EST today! |
|
FOCUS LISTπ |
VERO - Up over 27% in the pre-market after announcing exclusive strategic supply arrangement with Skin Laundry |
NRIX - Up over 14% in pre after positive results in Relapsed Refractory Chronic Lymphocytic Leukemia trial |
ZYME - Up over 9% in pre after receiving FDA clearance of Investigational New Drug Application for ZW171 targeting Bispecific Antibody for Mesothelin-expressing Cancers |
|
*sponsored by Shore Thing Media | Right now, there are a handful of stocks that are either in breakout continuation patterns or what I like to call "bottom bouncers." | There is really no better example of that than the stock I am about to show you. | Pull up N2OFF Inc. (NITO) and I'll show why I think it has all the potential I'm looking for right now. | Let's start by looking closely at the price chart… | | You can see that NITO has drifted lower over the last month on very light volume. It dropped all the way from $1 to $.60 without any really big selling pressure. | Now, look at what happened on Friday last week (I circled it for you above). | That is exactly what I would call a textbook "bottom bounce" play setting up. | We saw a flood of volume as the market attempted to find the bottom of this stock, which led to a small pop in the share price as well. | While you never truly know where a stock's bottom will be (other than $0!), when I see that type of action, it signals that traders are starting to get excited about the possibility of a reversal. | If NITO can regain its footing above $1 again, that would be a nearly 50% move higher from this oversold level. | For my full report on NITO, see the hot stock page. | As always, If you decide to trade anything, have a trading plan in place as trading is risky and nothing is ever guaranteed. | *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
|
|
HOTLISTπ₯ |
VERO - Up over 27% in the pre-market after announcing exclusive strategic supply arrangement with Skin Laundry |
Venus Concept Inc. (VERO) is a medical technology company that develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. |
In the pre-market this morning the company announced that it had reached a new exclusive strategic supply arrangement with Skin Laundry for resurfacing and skin tightening devices. |
The supply arrangement included an initial order for Venus Viva ("Viva") devices for their locations across the United States and the associated Viva tips consumable to complete the procedures. S |
Skin Laundry is placing the devices throughout their chain of clinics and plans to perform thousands of skin resurfacing treatments per month using Venus Concept's proprietary (MP)2 NanoFractional RF Technology with SmartScan, which provides clinically validated efficacy in both resurfacing and tightening. |
Venus Concept's (MP)2 technology provides both RF and PEMF for optimal collagen and elastin formation with over 9,000 systems installed globally. |
The stock traded up over 27% in the pre-market in reaction to the news. |
|
The $1.15 area acted as support in the pre-market and will be an important level to watch. |
Above it, targets to the upside are $1.30 and then the pre-market high at $1.35. Beyond that, $1.59, $1.80 and $2 come into play. |
Below $1.15, targets to the downside are $1 and then a gap fill at $0.9360. |
|
NRIX - Up over 14% in pre after positive results in Relapsed Refractory Chronic Lymphocytic Leukemia trial |
Nurix Therapeutics Inc. (NRIX) is a clinical stage biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. |
In the pre-market this morning, the company announced positive results for NX-5948 in its Relapsed Refractory Chronic Lymphocytic Leukemia trial, presented at the European Hematology Association Congress (EHA2024). |
The objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations |
Clinical responses in CLL patients were rapid and deepening with longer time on treatment |
Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 |
The stock traded up over 14% in the pre-market on the news. |
|
The first target for bulls is the pre-market high at $18.39. |
Beyond that, targets to the upside are $29 and $22. |
Below $18.39, targets to the downside are $17.09, $16.75, $16, $15.50 and then $15.18. |
|
HOT SUMMER SALE ON MARKET NAVIGATOR ENDS IN JUST |
|
|
|
|
ZYME - Up over 9% in pre after receiving FDA clearance of Investigational New Drug Application for ZW171 targeting Bispecific Antibody for Mesothelin-expressing Cancers |
Zymeworks Inc. (ZYME) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes biotherapeutics for the treatment of cancer. |
In the pre-market this morning, the company announced that the FDA has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. |
The Company expects to file applications seeking regulatory permission to commence clinical studies for ZW171 in other non-US jurisdictions in the second half of 2024. |
The stock traded up over 9% in the pre-market on the news. |
|
The first target for bulls is the pre-market high at $10.30. |
Beyond that, $10.80, $11, $11.50 and $12.50 come into play. |
Below $10.30, targets to the downside are $10, $9.70, $9.50 and a gap fill at $9.04. |
|
MARKET NEWS π° |
|
|
π Make sure you are getting my mobile text alerts – text "RAGE" to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the "1" at the front!). Don't miss out! |
|
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull |
|
*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." |
Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received sixty thousand dollars (cash) from Shore Thing Media for advertising N2OFF, Inc for a five day marketing program starting on June 17, 2024. This amount was paid by someone else not connected to N2OFF, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. |
Now, diving right into N2OFF, Inc might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. |
Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. |
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, |
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep's with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. |
So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
No comments:
Post a Comment